GNNS.F Stock Overview
An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Genscript Biotech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.39 |
| 52 Week High | HK$2.65 |
| 52 Week Low | HK$1.05 |
| Beta | 1.05 |
| 11 Month Change | -0.71% |
| 3 Month Change | n/a |
| 1 Year Change | -56.56% |
| 33 Year Change | -70.43% |
| 5 Year Change | -44.40% |
| Change since IPO | 56.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| GNNS.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -7.2% | -1.2% |
| 1Y | -56.6% | 1.2% | 30.4% |
Return vs Industry: GNNS.F underperformed the US Life Sciences industry which returned 1.2% over the past year.
Return vs Market: GNNS.F underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| GNNS.F volatility | |
|---|---|
| GNNS.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GNNS.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GNNS.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 7,284 | Weihui Shao | www.genscript.com |
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation.
Genscript Biotech Corporation Fundamentals Summary
| GNNS.F fundamental statistics | |
|---|---|
| Market cap | US$2.92b |
| Earnings (TTM) | -US$177.01m |
| Revenue (TTM) | US$1.01b |
2.9x
P/S Ratio-16.6x
P/E RatioIs GNNS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNNS.F income statement (TTM) | |
|---|---|
| Revenue | US$1.01b |
| Cost of Revenue | US$468.10m |
| Gross Profit | US$541.49m |
| Other Expenses | US$718.50m |
| Earnings | -US$177.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.083 |
| Gross Margin | 53.63% |
| Net Profit Margin | -17.53% |
| Debt/Equity Ratio | 48.1% |
How did GNNS.F perform over the long term?
See historical performance and comparison